Interview with Nancy Gillett, DVM, PhD, DACVP
Nancy Gillett, DVM, PhD, DACVP Corporate Executive Vice President & President, Global Preclinical Services, Charles River
Q&A
Q: You recently celebrated the one year anniversary of Charles River's Shanghai facility. What have you learned about the Asian market since opening last October?
A: First, let me update you on a huge milestone for the Shanghai facility. The site received accreditations from the Association for Assessment and Accreditation of Laboratory Animal Care, (AAALAC) the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC). These accreditations confirm our ability to provide clients with superior service in a regulatory compliant environment.
The interest in working in China continues to expand across our customer base. Multinational companies are developing R & D centers in China as part of their strategy to develop, license and distribute medicines globally. There is tremendous interest in not only the early discovery work to support the strong chemistry-based expertise that pharma companies are already utilizing in China, but also a desire to extend into the regulatory compliant studies necessary for regulatory approval. Finally we are also seeing an increased interest in large molecule and vaccine development in this region.
Q: What is next for Charles River in China?
A: Now that we have established ourselves in the Shanghai facility, we are currently exploring the option of opening a second China facility.
...To view the complete article, please login or subscribe if you don't already have an account.